welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

UK patients gain early access to Duchenne drug

UK patients can gain access to Santhera’s as-yet unapproved Duchenne muscular dystrophy drug via an early access scheme.

The Medicines and Healthcare products Regulatory Agency granted Raxone (idebenone) a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

As a result of the decision, patients aged 10 and above with respiratory function decline, who are not taking gluticorticoids, will be able to get access to Raxone ahead of formal approval by the European Medicines Agency.

UK Patients Gain Early Access To Duchenne Drug